GRAIL, Inc. (GRAL) stock surged +1.78%, trading at $60.71 on NASDAQ, up from the previous close of $59.65. The stock opened at $60.63, fluctuating between $59.39 and $63.98 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| May 18, 2026 | 60.60 | 63.98 | 59.39 | 60.71 | 420.84K |
| May 15, 2026 | 60.00 | 61.76 | 58.37 | 59.65 | 642.44K |
| May 14, 2026 | 60.47 | 63.51 | 60.10 | 61.80 | 666.82K |
| May 13, 2026 | 60.50 | 62.30 | 59.50 | 60.47 | 502.73K |
| May 12, 2026 | 60.02 | 62.76 | 59.11 | 61.98 | 415.56K |
| May 11, 2026 | 61.42 | 62.59 | 60.17 | 61.26 | 581.97K |
| May 08, 2026 | 62.89 | 63.00 | 60.58 | 61.64 | 537.3K |
| May 07, 2026 | 63.50 | 64.68 | 61.04 | 62.92 | 642.27K |
| May 06, 2026 | 56.00 | 63.74 | 53.01 | 62.75 | 1.25M |
| May 05, 2026 | 56.29 | 56.89 | 54.03 | 54.40 | 716.51K |
| May 04, 2026 | 53.80 | 55.68 | 53.27 | 55.66 | 482.51K |
| Apr 30, 2026 | 50.39 | 54.54 | 50.38 | 54.48 | 669.35K |
| Apr 29, 2026 | 51.41 | 51.63 | 49.15 | 49.69 | 559.56K |
| Apr 28, 2026 | 54.32 | 55.20 | 51.82 | 52.20 | 438.61K |
| Apr 27, 2026 | 54.42 | 55.88 | 53.88 | 55.02 | 447.75K |
| Apr 23, 2026 | 53.09 | 53.21 | 49.17 | 50.65 | 555.76K |
| Apr 22, 2026 | 52.23 | 52.79 | 51.61 | 52.60 | 415.86K |
| Apr 21, 2026 | 51.89 | 53.21 | 49.58 | 51.05 | 531.17K |
| Apr 20, 2026 | 50.64 | 51.91 | 50.01 | 51.20 | 349.84K |
| Apr 17, 2026 | 51.20 | 52.44 | 50.48 | 51.71 | 739.38K |
GRAIL, Inc., a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. It is also developing minimal residual disease and other post-diagnostic tests. The company was incorporated in 2015 and is based in Menlo Park, California. GRAIL, Inc. operates as a former subsidiary of Illumina, Inc.
| Employees | 1000 |
| Beta | 5.21 |
| Sales or Revenue | N/A |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | N/A |
| Sector | Healthcare |
| Industry | Medical - Diagnostics & Research |
© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep